March 27, 2019
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation […]